Dr. Amina Zoubeidi leads identification of gene linked to growth of aggressive neuroendocrine prostate cancer (NEPC)

Date Posted: 
2017-01-30

NEPC is a highly aggressive cancer that sometimes emerges in prostate cancer patients undergoing androgen deprivation therapy (ADT). Unfortunately ADT, which is common treatment for prostate cancer, had led to a correlating increase in cases of an aggressive variant called treatment-induced NEPC.
Dr. Zoubeidi’s discovery of the protein driving the emergence of NEPC is a timely and important one. It allowed her and her team to use the new genome editing CRISPR technology to turn off the gene producing that protein. They discovered that when it was turned off, the emergence of NEPC was prevented. Her work was published Cancer Discovery.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Terry Fox

Terry Fox Run - September 15, 2019

This year's Terry Fox Run takes place on Sunday September 15, in locations across Canada.  Please consider donating to or joining our TFRI-VPC team as we raise funds to enable The Terry Fox Foundation & The Terry Fox Research Institute to continue their support of innovative and progressive cancer research programs

Employment

Work at the Vancouver Prostate Centre

Monday, July 8, 2019

Dr. Flannigan to lead clinical trial for scrotal pain treatment

Monday, June 3, 2019

Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Dr. Chi